Compare SRL & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRL | HURA |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | China | United States |
| Employees | N/A | 19 |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.0M | 79.6M |
| IPO Year | 1996 | N/A |
| Metric | SRL | HURA |
|---|---|---|
| Price | $7.51 | $2.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 19.3K | ★ 763.1K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 14.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.13 | $0.41 |
| 52 Week High | $10.39 | $4.41 |
| Indicator | SRL | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 66.36 |
| Support Level | $7.27 | $1.66 |
| Resistance Level | $7.60 | $2.68 |
| Average True Range (ATR) | 0.25 | 0.22 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 32.56 | 97.07 |
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.